Kim Rand (Kim Rand-Hendriksen)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 17

Top Topics

Atrial Fibrillation

Top Venues

Dermatology and therapy

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

BMC health services research

Journal of patient-reported outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Dermatology and therapy 14 (3) (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Dermatology and therapy 14 (3) (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Dermatology and therapy 14 (3) (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Dermatology and therapy 14 (3) (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Dermatology and therapy 14 (3) (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis. Dermatology and therapy (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Dermatology and therapy (2024)
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José Carlos Armario-Hita
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis. Dermatology and therapy (2023)
Meixia Liao, Nan Luo, Kim Rand, Zhihao Yang
Urban/rural differences in preferences for EQ-5D-5L health states: a study of a multi-ethnic region in China. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2023)
Meixia Liao, Kim Rand, Zhihao Yang, Chien-Ning Hsu, Hsiang-Wen Lin, Nan Luo
Censoring in the time trade-off valuation of worse-than-dead EQ-5D-5L health states: can a time-based willingness-to-accept question be the solution? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2022)
Fredrik Andreas Dahl, Mathias Barra, Kashif Waqar Faiz, Hege Ihle-Hansen, Halvor Naess, Kim Rand, Ole Morten Rønning, Tone Breines Simonsen, Bente Thommessen, Angela Susan Labberton
Stroke unit demand in Norway - present and future estimates. BMC health services research 22 (1) (2022)
Tonya Moen Hansen, Knut Stavem, Kim Rand
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study. The European journal of health economics : HEPAC : health economics in prevention and care (2022)
Red Thaddeus D P Miguel, Adovich Sarmiento Rivera, Kent Jason Go Cheng, Kim Rand, Fredrick Dermawan Purba, Nan Luo, Ma-Ann Zarsuelo, Anne Julienne Genuino-Marfori, Irene Florentino-Fariñas, Anna Melissa Guerrero, Hilton Y Lam
Estimating the EQ-5D-5L value set for the Philippines. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 31 (9) (2022)
Tonya Moen Hansen, Knut Stavem, Kim Rand
Time trade-off with someone to live for: impact of having significant others on time trade-off valuations of hypothetical health states. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2021)
Kim Rand, Espen Ajo Arnevik, Espen Walderhaug
Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L. Journal of patient-reported outcomes 4 (1) (2020)
Kim Rand, Fredrik Andreas Dahl, Joe Viana, Ole Morten Rønning, Kashif Waqar Faiz, Mathias Barra
Fewer ischemic strokes, despite an ageing population: stroke models from observed incidence in Norway 2010-2015. BMC health services research 19 (1) (2019)
Mihir Gandhi, Ru-San Tan, Raymond Ng, Su Pin Choo, Whay Kuang Chia, Chee Keong Toh, Carolyn Su Ping Lam, Phong Teck Lee, Nang Khaing Zar Latt, Kim Rand, Xiangmei Ma, Nan Luo
Comparison of health state values derived from patients and individuals from the general population. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 26 (12) (2017)